Action Alert: Send the e-letter below to Secretary of Health & Human Services Kathleen Sebelius asking her to halt the hasty FDA review of Gilead’s Truvada as an HIV prevention pill.
The Food and Drug Administration (FDA) refuses to release documents regarding its contact with Gilead Sciences about the approval of the company’s drug Truvada for HIV prevention. The FDA is now hastily considering approval of this drug despite several failed clinical trials.